Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $EYPT
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | $33.00 | Buy | Citigroup |
10/16/2024 | Sector Outperform | Scotiabank | |
8/28/2024 | $15.00 | Buy | Jefferies |
1/22/2024 | $35.00 | Overweight | JP Morgan |
11/2/2023 | $20.00 | Buy | Mizuho |
4/21/2023 | $33.00 | Outperform | Robert W. Baird |
7/7/2022 | $21.00 | Buy | Chardan Capital Markets |
11/15/2021 | $15.00 → $24.00 | Buy | HC Wainwright & Co. |
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936. A live audio webcast of the event can be accessed via the Investors section of t
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
– Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME – WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., EyePoint's President and CEO, will present an update on enrollment for its ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 21,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on February 14, 2025. The grants were approved by the Compensation Committee
Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target
Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Scotiabank initiated coverage on EyePoint Pharmaceuticals
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
Jefferies initiated coverage on EyePoint Pharmaceuticals with a new price target
Jefferies initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
Director Ando Goran bought $39,750 worth of shares (5,000 units at $7.95), increasing direct ownership by 61% to 13,150 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
Director Zaderej Karen L. bought $99,750 worth of shares (12,500 units at $7.98), increasing direct ownership by 312% to 16,500 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
President and CEO Duker Jay S. converted options into 7,000 shares and covered exercise/tax liability with 2,055 shares, increasing direct ownership by 7% to 77,651 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
Chief Financial Officer Elston George converted options into 5,834 shares, increasing direct ownership by 8% to 75,550 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
Director Lurker Nancy converted options into 20,000 shares, increasing direct ownership by 11% to 205,436 units (SEC Form 4)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Pharmaceuticals Inc.
SCHEDULE 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936. A live audio webcast of the event can be accessed via the Investors section of t
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025 – – Conference call to be held today, February 5, 2025 at 8:00 a.m. ET – WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmac
EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024 – – Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable safety and efficacy – – Phase 2 VERONA trial of DURAVYU in DME fully enrolled with topline data anticipated in Q1 2025 – – $280.2 million of cash and investments on June 30, 2024, with cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026 – WATERTOWN, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera
Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)